Related Experiment Video
Updated: May 7, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers
1Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Background:
Genomic rearrangements at the fragile site FRA1E may disrupt the dihydropyrimidine dehydrogenase gene (DPYD) which is involved in 5-fluorouracil (5-FU) catabolism. In triple-negative breast cancer (TNBC), a subtype of breast cancer frequently deficient in DNA repair, we have investigated the susceptibility to acquire copy number variations (CNVs) in DPYD and evaluated their impact on standard adjuvant treatment.
Methods:
DPYD CNVs were analysed in 106 TNBC tumour specimens using multiplex ligation-dependent probe amplification (MLPA) analysis. Dihydropyrimidine dehydrogenase (DPD) expression was determined by immunohistochemistry in 146 tumour tissues.
Results:
In TNBC, we detected 43 (41%) tumour specimens with genomic deletions and/or duplications within DPYD which were associated with higher histological grade (P=0.006) and with rearrangements in the DNA repair gene BRCA1 (P=0.007). Immunohistochemical analysis revealed low, moderate and high DPD expression in 64%, 29% and 7% of all TNBCs, and in 40%, 53% and 7% of TNBCs with DPYD CNVs, respectively. Irrespective of DPD protein levels, the presence of CNVs was significantly related to longer time to progression in patients who had received 5-FU- and/or anthracycline-based polychemotherapy (hazard ratio=0.26 (95% CI: 0.07-0.91), log-rank P=0.023; adjusted for tumour stage: P=0.037).
Conclusion:
Genomic rearrangements in DPYD, rather than aberrant DPD protein levels, reflect a distinct tumour profile associated with prolonged time to progression upon first-line chemotherapy in TNBC.
Insights
Genomic rearrangements in the dihydropyrimidine dehydrogenase gene (DPYD) are common in triple-negative breast cancer (TNBC). These DPYD copy number variations are linked to improved outcomes with 5-FU-based chemotherapy.
Area of Science:
- Oncology
- Genetics
- Pharmacogenomics
Background:
- Genomic rearrangements at FRA1E can disrupt the dihydropyrimidine dehydrogenase (DPYD) gene, crucial for 5-fluorouracil (5-FU) metabolism.
- Triple-negative breast cancer (TNBC) often exhibits DNA repair deficiencies, potentially increasing susceptibility to DPYD copy number variations (CNVs).
Purpose of the Study:
- To investigate the occurrence of DPYD CNVs in TNBC.
- To evaluate the impact of DPYD CNVs on patient response to standard adjuvant chemotherapy.
Main Methods:
- DPYD CNVs were analyzed in 106 TNBC tumors using multiplex ligation-dependent probe amplification (MLPA).
- Dihydropyrimidine dehydrogenase (DPD) protein expression was assessed via immunohistochemistry in 146 TNBC tissues.
Main Results:
- 41% of TNBC tumors showed DPYD deletions/duplications, associated with higher histological grade and BRCA1 rearrangements.
- DPYD CNVs correlated with longer time to progression in patients receiving 5-FU- or anthracycline-based chemotherapy, irrespective of DPD protein levels.
- Patients with DPYD CNVs had a significantly better prognosis (HR=0.26, P=0.023).
Conclusions:
- Genomic rearrangements in DPYD, not aberrant DPD protein levels, define a tumor profile associated with prolonged response to first-line chemotherapy in TNBC.
- DPYD CNVs represent a potential predictive biomarker for chemotherapy response in TNBC.
More Related Videos
06:06High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
Related Concept Videos
Abnormal Proliferation
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancers Originate from Somatic Mutations in a Single Cell
Replicative Cell Senescence
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...